Vyne Therapeutics Inc. (VYNE)

Market Closed

27 Jul, 20:00

NASDAQ (CM)

28. 56

After Hours

36. 42

+7.86 +27.5385%

19.07M Market Cap

- P/E Ratio

- Div Yield

93,256 Volume

-1 Eps

$ 28.56

Previous Close

Investors:

Add Transaction

Day Range

23.37 28.72

Year Range

14.03 74.47

Want to track VYNE and more in your Portfolio? 🎯

Get Started For Free

VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript

Seekingalpha | 8 months ago

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.29 per share a year ago.

Zacks | 9 months ago

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago.

Zacks | 1 year ago

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $1.85 per share a year ago.

Zacks | 1 year ago

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $3.08 per share a year ago.

Zacks | 2 years ago

Blog Affiliate Program About Terms Privacy Help Contact Us